A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
NCT03637491
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent as follows:
1. Metastatic pancreatic ductal adenocarcinoma; or
2. Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or other comparable local or regional certification).
- Have had disease progression during or following at least 1 and not more than 2 prior lines of treatment for advanced or metastatic disease.
- Patients with NSCLC must have previously received treatment with an anti-PD-1 or anti-PD-L1 agent for advanced disease.
- Measurable disease as per RECIST v1.1 criteria.
- Provision of a baseline tumor sample.
- Age ≥18 years (Japanese patients must be ≥20 years old)
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
- Adequate bone marrow, renal and liver functions.
- Adequate cardiac function.
- Informed consent provided.
- Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.
- Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.
- Persisting toxicity related to prior therapy.
- Current use of immunosuppressive medication.
- Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis,
pulmonary fibrosis, uveitis or iritis.
- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.
- Diagnosis of myelodysplastic syndrome (MDS).
- Known symptomatic brain metastases requiring steroids.
- Known history of testing positive for HIV or hepatitis.
- Clinically significant (ie, active) cardiovascular disease.
- History of thromboembolic or cerebrovascular events.
- Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer
resistance protein (BCRP)
- Uncontrolled hypertension.
- Concurrent neuromuscular disorder that is associated with the potential of elevated
creatinine kinase.
- Known history of Gilbert's syndrome.
- History or current evidence of retinal degenerative disease, retinal vein occlusion
(RVO) or current risk factors for RVO.
- Other acute or chronic medical or psychiatric condition.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- Tampa, Florida
- Baltimore, Maryland
- Royal Oak, Michigan
- Raleigh, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Memphis, Tennessee
- Nashville, Tennessee
- Tyler, Texas
- Fairfax, Virginia
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- London, Ontario
- Ottawa, Ontario
- Montreal, Quebec
- Springdale, Arkansas
- Singapore,
- Fayetteville, Arkansas
- Rogers, Arkansas
- Encinitas, California
- San Marcos, California
- Aurora, Colorado
- Aurora, Colorado
- Lafayette, Indiana
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Houston, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Brussels,
- Gent,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | ||||
Official Title ICMJE | A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS | ||||
Brief Summary | This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects. | ||||
Detailed Description | This is a Phase 1b/2, open label, multi-center, safety, clinical activity, pharmacokinetic (PK), and pharmacodynamics (PD) study of combinations of avelumab, binimetinib and talazoparib in adult patients with metastatic pancreatic ductal adenocarcinoma and other locally advanced or metastatic KRAS- or NRAS-mutant solid tumors. The Phase 1b part of this study will initially assess doublet drug combinations to determine a recommended dose for further investigation. Following this, the recommended dose for the combination of avelumab, binimetinib and talazoparib (triplet) will be determined. The recommended doses for the doublet and triplet combinations will be used in the Phase 2 part of the study, which will assess the safety and preliminary anti-tumor activity of the study treatments. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 Phase 2 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE | Pancreatic Cancer | ||||
Intervention ICMJE |
| ||||
Study Arms ICMJE |
| ||||
Publications * | Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020 Jun 30;48(3):1101-1108. doi: 10.1042/BST20191092. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE | 122 | ||||
Original Estimated Enrollment ICMJE | 127 | ||||
Estimated Study Completion Date ICMJE | November 28, 2024 | ||||
Estimated Primary Completion Date | November 29, 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
| ||||
Listed Location Countries ICMJE | Belgium, Singapore, United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03637491 | ||||
Other Study ID Numbers ICMJE | B9991033 2018-000124-34 ( EudraCT Number ) | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor ICMJE | Pfizer | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
| ||||
PRS Account | Pfizer | ||||
Verification Date | November 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |